Guardant Health, Inc. (NASDAQ:GH) Holdings Cut by Candriam S.C.A.

Candriam S.C.A. lowered its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 352,492 shares of the company's stock after selling 13,653 shares during the quarter. Candriam S.C.A. owned about 0.29% of Guardant Health worth $10,769,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its position in shares of Guardant Health by 168.1% during the third quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company's stock worth $79,000 after acquiring an additional 2,153 shares during the last quarter. US Bancorp DE increased its holdings in Guardant Health by 33.8% during the 3rd quarter. US Bancorp DE now owns 33,022 shares of the company's stock worth $758,000 after purchasing an additional 8,346 shares during the last quarter. ARK Investment Management LLC raised its position in shares of Guardant Health by 233.5% in the 3rd quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company's stock valued at $34,701,000 after purchasing an additional 1,059,104 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its stake in shares of Guardant Health by 4.1% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 74,180 shares of the company's stock valued at $1,702,000 after buying an additional 2,894 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of Guardant Health during the third quarter worth approximately $34,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the firm's stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares in the company, valued at $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 2,668 shares of company stock worth $95,208 in the last three months. 5.50% of the stock is currently owned by insiders.

Guardant Health Price Performance

Shares of GH traded up $6.79 during mid-day trading on Tuesday, hitting $42.63. The company's stock had a trading volume of 4,237,261 shares, compared to its average volume of 2,130,969. The firm has a 50-day moving average price of $42.16 and a 200 day moving average price of $32.51. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The stock has a market capitalization of $5.26 billion, a price-to-earnings ratio of -11.97 and a beta of 1.50.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, equities analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analysts Set New Price Targets

GH has been the subject of several recent analyst reports. Scotiabank raised their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Piper Sandler upped their price objective on Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Raymond James reiterated an "outperform" rating and issued a $59.00 target price (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Barclays assumed coverage on Guardant Health in a report on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Twenty research analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health presently has a consensus rating of "Buy" and a consensus target price of $48.40.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.